Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 49: 1942-1945, 2003; 10.1373/clinchem.2003.021212
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tchernitchko, D.
Right arrow Articles by Girodon, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tchernitchko, D.
Right arrow Articles by Girodon, E.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2003;49:1942-1945.)
© 2003 American Association for Clinical Chemistry, Inc.


Technical Briefs

Clinical Evaluation of a Reverse Hybridization Assay for the Molecular Detection of Twelve MEFV Gene Mutations

Dimitri Tchernitchko1,*, Marie Legendre1,*, Andrée Delahaye1, Cécile Cazeneuve2, Florence Niel1, Michel Goossens1,2, Serge Amselem1,2 and Emmanuelle Girodon1,a

1 Service de Biochimie et de Génétique Moléculaire, Hôpital Henri Mondor, AP-HP, 94010 Créteil, France;
2 INSERM U468 Génétique Moléculaire et Physiopathologie, 94010 Créteil, France

aaddress correspondence to this author at: Service de Biochimie et de Génétique Moléculaire–INSERM U468, Hôpital Henri Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; fax 33-1-4981-2842, e-mail emmanuelle.girodon@im3.inserm.fr

The first 300 words of the full text of this article appear below.

Familial Mediterranean fever (FMF) is an autosomal-recessive disorder (MIM 249100) characterized by recurrent attacks of fever and serositis, affecting principally Sephardic Jewish, Armenian, Arab, and Turkish populations. Early diagnosis is important to initiate colchicine therapy, which prevents the occurrence of attacks and of renal amyloidosis, the major complication of the disease. The identification of MEFV (1)(2), the gene responsible for the disease, allowed the use of an early molecular test of diagnostic value for FMF patients (3), which negates the needs for unnecessary invasive investigations. The MEFV gene, located on chromosome 16p13.3, contains 10 exons and encodes the marenostrin/pyrin protein, a molecule acting as a regulator of the proinflammatory interleukin-1-dependent pathway and of the apoptosis mediated by the apoptosis-associated Speck-like protein containing a CARD (ASC) (4)(5), and which belongs to the death domain-fold family (6).

More than 40 different FMF-associated mutations have been described to date (7), the most frequent ones being located in exon 10. Indeed, the M694V, V726A, M680I, and M694I mutations account for 65–95% of FMF alleles depending on the ethnic origin of the patient (8). E148Q is a frequent sequence variation situated in exon 2, but its involvement in the development of the disease remains controversial (9). The molecular diagnosis of FMF is based on various methods, including tedious and time-consuming scanning techniques such as denaturing gradient gel electrophoresis (DGGE) (3) or direct sequencing (10). Restriction enzyme analysis enables the detection of known mutations but still requires multiple DNA amplifications. An in-house amplification refractory mutation system has been designed, but it detects only three mutations (11). Because the spectrum of the most frequent mutations in FMF has been characterized in all at-risk . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Rheumatology (Oxford)Home page
Q. Yao and D. E. Furst
Autoinflammatory diseases: an update of clinical and genetic aspects
Rheumatology, July 1, 2008; 47(7): 946 - 951.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
E. Hultin, M. Kaller, A. Ahmadian, and J. Lundeberg
Competitive enzymatic reaction to control allele-specific extensions
Nucleic Acids Res., March 14, 2005; 33(5): e48 - e48.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. Touitou
Standardized Testing for Mutations in Familial Mediterranean Fever
Clin. Chem., November 1, 2003; 49(11): 1781 - 1782.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.